Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 64,083 shares changed hands during trading, an increase of 146% from the previous session's volume of 26,033 shares.The stock last traded at $18.12 and had previously closed at $18.40.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the company. William Blair raised Telix Pharmaceuticals Limited American Depositary Shares to a "strong-buy" rating in a research report on Tuesday, November 19th. UBS Group boosted their price objective on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a "buy" rating in a report on Monday, January 27th.
Read Our Latest Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 3.0 %
The business has a fifty day moving average of $17.28.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
